Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

572 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis.
Chitnis T, Foley J, Ionete C, El Ayoubi NK, Saxena S, Gaitan-Walsh P, Lokhande H, Paul A, Saleh F, Weiner H, Qureshi F, Becich MJ, da Costa FR, Gehman VM, Zhang F, Keshavan A, Jalaleddini K, Ghoreyshi A, Khoury SJ. Chitnis T, et al. Among authors: qureshi f. Clin Immunol. 2023 Aug;253:109688. doi: 10.1016/j.clim.2023.109688. Epub 2023 Jul 4. Clin Immunol. 2023. PMID: 37414379 Free article.
Proteomic signatures of physical, cognitive, and imaging outcomes in multiple sclerosis.
Jalaleddini K, Jakimovski D, Keshavan A, McCurdy S, Leyden K, Qureshi F, Ghoreyshi A, Bergsland N, Dwyer MG, Ramanathan M, Weinstock-Guttman B, Benedict RH, Zivadinov R. Jalaleddini K, et al. Among authors: qureshi f. Ann Clin Transl Neurol. 2024 Mar;11(3):729-743. doi: 10.1002/acn3.51996. Epub 2024 Jan 17. Ann Clin Transl Neurol. 2024. PMID: 38234075 Free PMC article.
Complement Activation Is Associated With Disease Severity in Multiple Sclerosis.
Oechtering J, Stein K, Schaedelin SA, Maceski AM, Orleth A, Meier S, Willemse E, Qureshi F, Heijnen I, Regeniter A, Derfuss T, Benkert P, D'Souza M, Limberg M, Fischer-Barnicol B, Achtnichts L, Mueller S, Salmen A, Lalive PH, Bridel C, Pot C, Du Pasquier RA, Gobbi C, Wiendl H, Granziera C, Kappos L, Trendelenburg M, Leppert D, Lunemann JD, Kuhle J; Swiss MS Cohort Study. Oechtering J, et al. Among authors: qureshi f. Neurol Neuroimmunol Neuroinflamm. 2024 Mar;11(2):e200212. doi: 10.1212/NXI.0000000000200212. Epub 2024 Feb 14. Neurol Neuroimmunol Neuroinflamm. 2024. PMID: 38354323 Free article.
A US payer perspective health economic model assessing value of monitoring disease activity to inform discontinuation and re-initiation of DMT in multiple sclerosis.
Jalaleddini K, Bermel RA, Talente B, Weinstein D, Qureshi F, Rasmussen M, Menon S, Amarapala M, Jordan K, Ghoreyshi A, McCurdy S, Edgeworth M. Jalaleddini K, et al. Among authors: qureshi f. Mult Scler. 2024 Mar;30(3):432-442. doi: 10.1177/13524585241227372. Epub 2024 Feb 19. Mult Scler. 2024. PMID: 38374525
Distinct plasma lipids predict axonal injury and multiple sclerosis activity.
Schoeps VA, Bhargava P, Virupakshaiah A, Ladakis DC, Moseley C, Chong J, Aaen G, Graves JS, Benson L, Gorman MP, Rensel M, Abrams A, Mar S, Lotze TE, Chitnis T, Waldman A, Krupp L, Rodriguez M, Tillema JM, Rose J, Schreiner T, Qureshi F, Peterson S, Barcellos LF, Casper TC, Newman J, Borkowski K, Waubant E; US Network of Pediatric MS Centers. Schoeps VA, et al. Among authors: qureshi f. J Neurol Neurosurg Psychiatry. 2024 Sep 12:jnnp-2024-333652. doi: 10.1136/jnnp-2024-333652. Online ahead of print. J Neurol Neurosurg Psychiatry. 2024. PMID: 39266284
572 results